A phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not candidates for high-dose chemotherapy: Results of a planned interim safety analysis

Category Primary study
JournalBlood
Year 2011
This article has no abstract
Epistemonikos ID: 0256ac30044368fb69268b9c6845b25ab9629fb3
First added on: Feb 05, 2025